Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen - PubMed
12 hours ago
- #Glioblastoma
- #Oncolytic virus
- #Immunotherapy
- Oncolytic virus M1 (OVM) reinvigorates CD8+ T-cell immunity against glioblastoma (GBM).
- OVM reverses GBM-driven systemic immunosuppression and promotes T-cell infiltration in the tumor microenvironment (TME).
- Intravenous OVM suppresses glioma progression in a spleen-dependent manner.
- OVM enhances B-cell-T-cell interactions in the spleen via immune synapse formation.
- Bst2+ B cells in the spleen exhibit superior antigen cross-presentation, activating CD8+ T cells against GBM.
- OVM synergizes with anti-PD-1 therapy, extending survival in glioma-bearing animals.
- The study highlights OVM's therapeutic potential for GBM and its immunomodulatory mechanism.